Protein S Activity Test

Your body runs a constant balancing act between forming blood clots (to stop bleeding) and dissolving them (to keep blood flowing). Protein S activity measures how well one side of that equation is working. When protein S is low, your blood has a harder time shutting down clotting once it starts, and that imbalance can set the stage for dangerous clots in the legs or lungs, sometimes years before one actually forms.

What makes this test especially valuable is that standard blood work never checks it. You can have perfectly normal cholesterol, blood counts, and metabolic panels while carrying a clot-prevention deficit that raises your risk of venous thromboembolism (blood clots in veins) by two to fourteen times, depending on how severe the deficiency is. This is the kind of risk that only shows up if you look for it.

How Protein S Keeps Your Blood Flowing

Protein S (the "S" stands for Seattle, where it was first discovered) works as a helper molecule for your body's main clot-prevention system. It circulates in your blood in two forms: about 40% floats freely, and about 60% is bound to a carrier protein called C4b-binding protein. Only the free form is fully active as an anticoagulant.

The free protein S does its job in three ways. First, it boosts the activity of another anticoagulant called activated protein C (APC), helping APC break down two key clotting factors (factor Va and factor VIIIa) that would otherwise drive excessive clot formation. Second, it helps another clot-prevention molecule called tissue factor pathway inhibitor (TFPI) block a different clotting trigger. Third, it directly inhibits parts of the clotting machinery on its own. Together, these three roles make protein S one of your body's most versatile natural blood thinners.

Venous Thromboembolism Risk

The strongest and most consistent link between low protein S and disease is venous thromboembolism (VTE), which includes deep vein thrombosis (blood clots in deep veins, usually in the legs) and pulmonary embolism (clots that travel to the lungs). The size of the risk depends on how and why protein S is low.

A 2025 study in JAMA analyzed over 600,000 people from the UK Biobank and the NIH All of Us research program. People with severe genetic deficiency (complete loss-of-function mutations in the PROS1 gene) had roughly 14 times the odds of VTE compared to the general population. Less severe genetic variants approximately doubled the risk. These genetic deficiencies are rare (about 1 in 10,000 people carry the severe form), but the consequences are serious.

The same study revealed something that changes how we think about protein S testing: low protein S levels predicted increased VTE risk regardless of whether a genetic mutation was present. Even after removing everyone with a known PROS1 gene variant, people with low protein S still had about 1.7 times the odds of VTE. This means acquired causes of low protein S (younger age, lower body weight, oral contraceptive use, inflammation) carry real thrombotic risk, not just the inherited form.

Sources: Chaudhry et al., JAMA 2025; Bucciarelli et al., Journal of Thrombosis and Haemostasis 2012.

What this means for you: even borderline-low protein S levels (not just severely deficient ones) carry measurable VTE risk. If your result falls below the normal range, it is worth retesting to confirm and discussing preventive strategies during high-risk periods like surgery, long flights, or pregnancy.

Arterial Clots: A Different Story

The relationship between protein S and arterial blood clots (heart attacks, strokes) is much less clear than the venous connection. The 2025 JAMA study found that genetic protein S deficiency was not associated with heart attack or non-cardioembolic stroke. However, low plasma protein S levels (regardless of genetics) were associated with peripheral artery disease after statistical correction, though the authors interpreted this as protein S possibly being a marker of vascular disease rather than a cause.

A meta-analysis of 68 studies covering nearly 12,000 stroke patients found about a twofold increased risk of arterial ischemic stroke with protein S deficiency, but this relied heavily on case-control studies with potential selection bias. A family cohort study found about 4.6 times higher risk of arterial clots specifically in people under 55 with hereditary protein S deficiency, but no increased risk after that age. Given these mixed findings, protein S testing is most clearly useful for assessing venous clot risk, not arterial disease.

Pregnancy and Recurrent Pregnancy Loss

Protein S levels naturally decline during pregnancy. Total protein S drops to roughly 15 mg/L in the second trimester from a baseline of about 24 mg/L, and free protein S falls even further toward delivery. This normal physiological decrease makes testing during pregnancy unreliable for diagnosing a true deficiency.

For women with known protein S deficiency and a personal or strong family history of VTE, the absolute risk of a pregnancy-related clot may reach 5 to 7%. ACOG guidelines note that protein S deficiency is an established risk factor for pregnancy-associated VTE. However, current evidence does not support routine thrombophilia screening in women with recurrent pregnancy loss, preeclampsia, or fetal growth restriction, because anticoagulation treatment has not been shown to prevent these outcomes. A 2023 randomized trial (ALIFE2) found no benefit of heparin for women with recurrent miscarriage and inherited thrombophilia.

Inherited vs. Acquired Deficiency

There are three types of inherited protein S deficiency. Type I means both the amount and activity are low. Type II means the amount is normal but the protein does not work properly. Type III means the free (active) form is low even though total protein S looks normal. All three types are caused by mutations in the PROS1 gene.

But here is the finding that reshaped this field: the 2025 JAMA study showed that genetic mutations explain only a tiny fraction of all low protein S levels in the population. The vast majority of people with low protein S have acquired deficiency, caused by factors like younger age, lower body mass, oral contraceptive use, pregnancy, liver disease, inflammation, or vitamin K antagonist therapy. This matters because acquired low levels still carry increased VTE risk, even without a genetic cause.

Reference Ranges

Protein S activity is reported as a percentage of normal, with 100% representing the average in a healthy population. Reference ranges vary by lab, assay method, sex, and age. Men generally have higher levels than women, especially before menopause. Always compare your results within the same lab over time for the most meaningful trend.

These tiers are drawn from published research including the Italian VTE study and French cohort data. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. Sex-specific and age-specific reference ranges improve accuracy, so ask your lab whether their normal range accounts for these factors.

When Results Can Be Misleading

Protein S activity has a within-person biological variation (the normal fluctuation in the same individual from day to day) of about 8 to 12%. That means a single low reading does not necessarily reflect your true baseline. Several common situations can produce falsely low or falsely high results.

• Acute illness or inflammation: When your body mounts an inflammatory response, a carrier protein called C4b-binding protein rises. This carrier grabs more free protein S and converts it to the inactive bound form, producing a falsely low activity reading even though your total protein S may be normal or elevated. Winter respiratory infections alone decreased free protein S by about 27% in one study.
• Oral contraceptives: Birth control pills reduce free protein S by 15 to 35%, with third-generation formulations (containing desogestrel, norgestimate, or gestodene) causing greater drops than second-generation pills. If you are on hormonal contraception, your result may appear deficient when your underlying protein S production is normal.
• Medications that interfere with the assay: Direct oral anticoagulants like rivaroxaban, apixaban, and edoxaban can cause falsely elevated protein S activity readings on clot-based assays. Direct thrombin inhibitors (argatroban, bivalirudin) produce similar interference. Free protein S antigen measured by a different method (immunoassay) is not affected by these drugs.
• Lupus anticoagulant and elevated Factor VIII: Lupus anticoagulant causes falsely elevated protein S activity, potentially masking a true deficiency. Elevated Factor VIII (common during acute illness) causes the opposite problem: falsely low activity readings even when free protein S is actually normal.

For the most reliable result, test when you are healthy (at least 2 to 4 weeks after any illness or surgery), not pregnant, and ideally not taking oral contraceptives or anticoagulants. If you must test while on medication, inform your provider so the result can be interpreted in context.

Tracking Your Trend

A single protein S activity reading is a snapshot taken on one particular day, subject to the 8 to 12% natural fluctuation and the confounders described above. This is exactly why the International Society on Thrombosis and Haemostasis (ISTH) recommends at least two separate measurements, taken weeks to months apart, before diagnosing protein S deficiency.

If your first result is low, do not assume you have a permanent deficiency. Retest in 4 to 8 weeks under optimal conditions: no acute illness, no hormonal contraception if possible, and not during pregnancy. If both readings are low, you have a confirmed finding worth investigating further, potentially with genetic testing of the PROS1 gene and evaluation of acquired causes.

For people with confirmed deficiency who are being monitored, annual retesting helps track whether levels are stable or declining. If you are managing an acquired cause (such as stopping oral contraceptives), a follow-up test in 3 to 6 months can confirm whether your levels have normalized. Because protein S has high individual variability but relatively stable levels within the same person over time (when confounders are controlled), your personal trend is far more informative than comparing a single number to a population reference range.